NBIX
Neurocrine Biosciences, Inc.

3,244
Mkt Cap
$13.57B
Volume
30.00
52W High
$160.18
52W Low
$84.23
PE Ratio
32.49
NBIX Fundamentals
Price
$136.06
Prev Close
$137.96
Open
$136.63
50D MA
$142.83
Beta
0.71
Avg. Volume
952,959.59
EPS (Annual)
$3.29
P/B
4.52
Rev/Employee
$1.31M
Loading...
Loading...
News
all
press releases
Atle Fund Management AB Has $14.41 Million Position in Neurocrine Biosciences, Inc. $NBIX
Atle Fund Management AB boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 16.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Y Intercept Hong Kong Ltd Makes New Investment in Neurocrine Biosciences, Inc. $NBIX
Y Intercept Hong Kong Ltd bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·2d ago
News Placeholder
AlphaQuest LLC Boosts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
AlphaQuest LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3,271.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·2d ago
News Placeholder
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Buy Rating by Wall Street Zen
Wall Street Zen downgraded Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Saturday...
MarketBeat·2d ago
News Placeholder
Summit Global Investments Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX
Summit Global Investments raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 214.0% in the 3rd quarter, according to the company in its most recent...
MarketBeat·3d ago
News Placeholder
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Mitsubishi UFJ Trust & Banking Corp
Mitsubishi UFJ Trust & Banking Corp trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 21.0% during the third quarter, according to the company in its most recent 13F...
MarketBeat·4d ago
News Placeholder
Neurocrine Biosciences, Inc. $NBIX Holdings Lifted by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 113.8% during the third quarter, according to the company in its...
MarketBeat·7d ago
News Placeholder
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in...
PR Newswire·7d ago
News Placeholder
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from Analysts
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twenty-three brokerages that are covering the firm, Marketbeat reports. Six...
MarketBeat·8d ago
News Placeholder
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $178.00 at UBS Group
UBS Group cut their target price on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a "buy" rating on the stock in a research report on Friday...
MarketBeat·10d ago
<
1
2
...
>

Latest NBIX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.